Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual Meeting

Rhea-AI Summary

Adicet Bio, Inc. (Nasdaq: ACET) announced a poster presentation for its allogeneic gamma delta CAR T cell therapy, ADI-002, at the Society for Immunotherapy of Cancer's 36th Annual Meeting, scheduled for November 10-14, 2021. The poster, titled "ADI-002: an IL-15 armored allogeneic 'off-the-shelf' Vδ1 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3)," will be presented from November 12-14, 2021. This development emphasizes Adicet's focus on innovative cancer therapies and marks a significant step in its clinical strategy.

Positive

• Presentation of promising data for ADI-002, which targets glypican-3 in solid tumors.
• Participation in a significant industry event, potentially enhancing visibility and investor interest.

Negative

• None.

MENLO PARK, Calif. and BOSTON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the Company will present data in the form of a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 36^th Annual Meeting to be held November 10-14, 2021.

Details of the poster presentation:

Title: ADI-002: an IL-15 armored allogeneic “off-the-shelf” Vδ1 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3)

Abstract number: 119

Date: November 12-14, 2021

Poster viewing session: 7:00am - 5:00pm ET

About Adicet Bio, Inc.

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio, Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com 

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com

FAQ

What is the significance of Adicet Bio's ADI-002 presentation?

The ADI-002 presentation at the SITC Annual Meeting highlights advancements in allogeneic CAR T cell therapies for cancer, particularly targeting solid tumors.

When will Adicet Bio's ADI-002 poster be presented?

The poster for ADI-002 will be presented from November 12-14, 2021, at the Society for Immunotherapy of Cancer Annual Meeting.

What is the focus of Adicet Bio's ADI-002 therapy?

ADI-002 focuses on an IL-15 armored gamma delta CAR T cell therapy targeting glypican-3 (GPC3) in solid tumors.

Where can I find more information about Adicet Bio?

More information about Adicet Bio, Inc. can be found on their official website at http://www.adicetbio.com.